Clinical trials: Malaria, completed
Pregnancy, Malaria
Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy
The study aims at comparing the safety, tolerability and efficacy of Mefloquine (MQ) to Sulfadoxine-Pyrimethamine (SP) as Interment Preventive Treatment in pregnancy (IPTp) for the prevention of malaria effects on the mother and…
- Conditions
- Pregnancy, Malaria, HIV Infections
- Trial name
- MiPPAD (NCT00811421)
- Testing
- Sulphadoxine-pyrimethamine, Mefloquine (full dose), Mefloquine (split dose)
- Where
- 5 sites in Benin, Gabon and 3 more
- Volunteers
- 5,820 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Malaria in Pregnancy
Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine in Papua, Indonesia
Malaria in pregnancy is a major cause of maternal and neonatal death in Papua, Indonesia. A recent trial in Papua showed that monthly intermittent preventive treatment (IPTp) with the long-acting artemisinin-based combination…
- Trial name
- STOPMiP-2 (NCT05294406)
- Testing
- Intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine
- Where
- Indonesia
- Volunteers
- 2,128 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Drug Resistant Malaria, Asymptomatic Infections
Drug Resistance Among Asymptomatic Infection
A cross-sectional study will be conducted in selected 2 sentinel sites for assessment of drug resistance falciparum and vivax among asymptomatic infection in migrant workers in Myanmar.
- Conditions
- Drug Resistant Malaria, Asymptomatic Infections, Migrant Workers
- Trial name
- NCT03648411
- Testing
- Drug resistance molecular markers
- Where
- Burma
- Volunteers
- 765 people, healthy volunteers welcome
- Sponsor
- Department of Medical Research, Lower Myanmar
Plasmodium Falciparum Infection
Malaria Challenge With NF54 Strain
The purpose of this study is to determine how many infected mosquito bites are required to reliably give volunteers a case of malaria. It is expected that volunteers will develop malaria and may have symptoms.
- Trial name
- NCT00744133
- Testing
- NF54 P. falciparum isolate
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria Falciparum, Malaria Infection
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a first-in-humans randomized, double-blind, placebo-controlled, age de-escalation Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine…
- Trial name
- NCT06652737
- Testing
- PfSPZ-LARC2 Vaccine
- Where
- Burkina Faso
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Healthy, Non-smokers
A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers
This is a pilot study of a protocol for inducing a falciparum malaria infection in healthy volunteers in order to test the activity of novel agents being developed as drugs for the treatment of uncomplicated malaria.
- Trial name
- NCT01055002
- Testing
- Blood stage parasite (BSP) inoculum
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects
This study will examine safety of single doses of GSK369796 in healthy subjects, along with some test to examine how quickly GSK369796 gets in your blood, and how long it takes your body to get rid of it.
- Trial name
- NCT00675064
- Testing
- GSK369796
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vivax Malaria
Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan
This is an open label two-arm randomized prospective study of two treatments for P. vivax malaria. Patients meeting study inclusion criteria will be enrolled and allocated either chloroquine alone or chloroquine plus primaquine…
- Trial name
- VRA (NCT01178021)
- Testing
- Chloroquine, Chloroquine/Primaquine
- Where
- 3 sites in Afghanistan
- Volunteers
- 593 people
- Sponsor
- University of Oxford
Malaria, Diagnoses Disease
Clinical Validation of Novel Malaria Diagnostic Tools for POC Point-of-Care Testing
The aim of this study is to perform a performance evaluation of novel diagnostic tools for detecting malaria in malaria-endemic countries.
- Conditions
- Malaria, Diagnoses Disease, RDT
- Trial name
- NCT06225700
- Where
- Rwanda
- Volunteers
- 509 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Malaria
Parasite Clearance and Protection From Infection (PCPI) in Cameroon
The Cameroon PCPI study will measure the effect of the parasite genotypes associated with SP resistance on parasite clearance and protection from infection when exposed to SP.
- Trial name
- NCT06173206
- Testing
- SP (Macleods Pharmaceuticals Ltd), SPAQ (Guilin Pharmaceuticals), AS (Guilin Pharmaceuticals)
- Where
- Cameroon
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Hemoglobin Mutations, Erythrocyte Variants
Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research
This study will collect blood samples for use in laboratory studies of malaria. The World Health Organization reports that 40 percent of the world's population is at risk for malaria, mostly in the poorest countries.
- Trial name
- NCT00277849
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection
Malaria, a disease caused by the parasite Plasmodium, is one of the world's major infectious diseases. With approximately 627.000 deaths a year, it is both a chief cause of morbidity and mortality as well as a significant…
- Trial name
- BMGF2b (NCT02098590)
- Testing
- CPS-immunization, malaria challenge infection, P. falciparum NF135.C10, malaria challenge infection, P. falciparum NF166.C8
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria, Falciparum
Mass-Drug Administration to Reduce Malaria Transmission
In the 1950s, the WHO included mass drug administration (MDA) with antimalarial drugs as a tool for malaria control in 'exceptional conditions when conventional control strategies have failed'.
- Trial name
- MDATRANS (NCT00509015)
- Testing
- Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Artesunate (day 1,2,3: 4 mg/kg), Primaquine-base (day 3: 0.75 mg/kg)
- Where
- Tanzania
- Volunteers
- 6,000 people
- Sponsor
- Radboud University Medical Center
Malaria
Repellents as Added Control Measure to Long Lasting Insecticidal Nets
The scaling up of Long Lasting Insecticidal Nets (LLIN) and the expansion of Indoor Residual Spraying (IRS) has contributed to a significant decrease of malaria worldwide.
- Trial name
- MalaResT (NCT01663831)
- Testing
- Mosquito topical repellent
- Where
- Cambodia
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria, Anaemia
Efficacy of Three Novel Bi-treated Long Lasting Insecticidal Nets
The massive scale-up of Long Lasting Insecticidal Nets (LLIN) has led to a major reduction in malaria burden (up to 50%) in many sub-Saharan African countries.
- Trial name
- NCT03554616
- Testing
- Chlorfenapyr LLIN, pyriproxyfen LLIN, Piperonyl butoxide LLIN
- Where
- Tanzania
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique
This study aims to provide National Malaria Control Programs (NMCP), international donors and other key stakeholders with clear evidence on the impact and cost-effectiveness of using indoor residual spraying (IRS) with a…
- Trial name
- COST (NCT02910934)
- Testing
- Actellic CS
- Where
- 2 sites in United States, Mozambique
- Volunteers
- 3,915 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria
Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria
The purpose of this study is to test the safety and effectiveness of a new malaria vaccine, the DNA-Ad vaccine. The study is specifically looking at a vaccine regimen against Plasmodium falciparum, the most deadly form of malaria.
- Trial name
- DNA-Ad (NCT00870987)
- Testing
- DNA vaccine prime, adenovirus type 5 vaccine boost
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine
Mass Drug Administration (MDA) and Mass Screening and Selective Treatment (MST) might be applied as strategies for eliminating malaria when focusing on transmission stages.
- Trial name
- NCT01878357
- Testing
- dihydroartemisinin-piperaquine, primaquine
- Where
- Indonesia
- Volunteers
- 1,488 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Malaria, Effectiveness
Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malaria
Objective: to measure the effectiveness and safety of (artemether-lumefantrine) AL and (dihydroartemisinin-piperaquine) DP in patients (> 6 months) suffering from uncomplicated P. falciparum malaria.
- Trial name
- NCT04897919
- Testing
- Dihydroartemisinin-piperaquine 160 mg/20 mg Oral Tablet, Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
- Where
- Guinea-Bissau
- Volunteers
- 474 people
- Sponsor
- Bandim Health Project
Malaria
Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet
The primary objective of this study is to determine the bioequivalence of the combination of pyronaridine and artesunate (180:60mg) to-be-marketed tablet to the clinical trial reference tablet administered as a single total dose…
- Trial name
- NCT00682630
- Testing
- pyronaridine artesunate clinical trial reference tablets, pyronaridine artesunate to-be-marketed tablets
- Where
- Switzerland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.